BEIJING, July 25 (Xinhua) -- AstraZeneca is intensifying its commitment to China, deepening investments in research, manufacturing, and partnerships as the British pharmaceutical company seeks to tap into the opportunities presented by the country's rise as a global hub for healthcare innovation.
"We are really trying to broaden and expand our partnership in China," Iskra Reic, AstraZeneca executive vice president, international, told Xinhua in a recent interview.
Noting that China is a global leader in healthcare innovation, she said the number of medicines developed in China at AstraZeneca has doubled over the last four years.
The company's local footprint has grown substantially since entering the Chinese market in 1993. It has established global production hubs in the cities of Wuxi, Taizhou and Qingdao, which supply high-quality medicines to more than 70 markets worldwide.
Earlier this year, the company announced an investment of $2.5 billion to establish a global strategic R&D center in Beijing, following the one set up in Shanghai a few years ago.
AstraZeneca's push in China aligns with its broader goals to help advance the Healthy China 2030 initiative and expand access to quality healthcare. Focusing on therapeutic areas where Chinese patients have the most urgent needs, it has introduced over 40 innovative drugs to China.
Collaboration with Chinese innovators is also a key component of AstraZeneca's strategy. Over the past two years, it has signed global licensing agreements with 14 Chinese biotech companies. Through its healthcare investment fund, the company is also supporting 27 Chinese biotechs in their global expansion efforts.
These progresses, she noted, reflect AstraZeneca's "sustained commitment to China and our confidence in its innovation."
The company has attended the China International Supply Chain Expo for three consecutive years, highlighting its China partnership and vision for a sustainable, healthy future.
"We truly believe that China's innovation in the healthcare space can make a huge impact to tackle global healthcare challenges in the years to come," she added.
BEIJING, July 25 (Xinhua) -- AstraZeneca is intensifying its commitment to China, deepening investments in research, manufacturing, and partnerships as the British pharmaceutical company seeks to tap into the opportunities presented by the country's rise as a global hub for healthcare innovation.
"We are really trying to broaden and expand our partnership in China," Iskra Reic, AstraZeneca executive vice president, international, told Xinhua in a recent interview.
Noting that China is a global leader in healthcare innovation, she said the number of medicines developed in China at AstraZeneca has doubled over the last four years.
The company's local footprint has grown substantially since entering the Chinese market in 1993. It has established global production hubs in the cities of Wuxi, Taizhou and Qingdao, which supply high-quality medicines to more than 70 markets worldwide.
Earlier this year, the company announced an investment of $2.5 billion to establish a global strategic R&D center in Beijing, following the one set up in Shanghai a few years ago.
AstraZeneca's push in China aligns with its broader goals to help advance the Healthy China 2030 initiative and expand access to quality healthcare. Focusing on therapeutic areas where Chinese patients have the most urgent needs, it has introduced over 40 innovative drugs to China.
Collaboration with Chinese innovators is also a key component of AstraZeneca's strategy. Over the past two years, it has signed global licensing agreements with 14 Chinese biotech companies. Through its healthcare investment fund, the company is also supporting 27 Chinese biotechs in their global expansion efforts.
These progresses, she noted, reflect AstraZeneca's "sustained commitment to China and our confidence in its innovation."
The company has attended the China International Supply Chain Expo for three consecutive years, highlighting its China partnership and vision for a sustainable, healthy future.
"We truly believe that China's innovation in the healthcare space can make a huge impact to tackle global healthcare challenges in the years to come," she added.
浑身乏力吃什么药 | 农历8月是什么月 | ki是什么意思 | yp是什么意思 | diff什么意思 |
im什么意思 | 同房时阴道疼痛是什么原因 | 晕车喝什么饮料好 | 女生流白带意味着什么 | 静脉曲张挂什么号 |
牙痛吃什么药好得快 | 老年人脚浮肿是什么原因 | 乳头为什么会痛 | 五子登科是什么意思 | 浑身麻是什么原因 |
孕妇钙片什么时间段吃最好 | 用盐袋子热敷小肚子有什么功效 | 股骨头坏死是什么原因引起的 | 屈膝是什么意思 | ccf是什么 |
人艰不拆是什么意思hcv9jop5ns3r.cn | 测智力去医院挂什么科hcv8jop7ns8r.cn | g6pd是什么xianpinbao.com | 11月有什么节日mmeoe.com | dr是什么hcv9jop2ns9r.cn |
口腔上颚疼是什么原因hcv9jop5ns1r.cn | 69式是什么意思hcv8jop5ns7r.cn | 长白头发了吃什么才能把头发变黑hcv7jop9ns2r.cn | 二十年婚姻是什么婚hcv8jop6ns6r.cn | 肝功能看什么科室hcv8jop5ns0r.cn |
多喝水有什么好处和坏处hcv8jop4ns6r.cn | 插管是什么意思hcv9jop6ns1r.cn | 哥弟属于什么档次hcv8jop6ns8r.cn | 烘焙是什么意思hcv9jop3ns8r.cn | 摄影三要素是什么hcv8jop0ns8r.cn |
上感是什么意思hcv9jop2ns0r.cn | 家家酒是什么意思hcv9jop1ns5r.cn | 此言差矣是什么意思hcv9jop3ns9r.cn | 蒙古族信仰什么教mmeoe.com | 人生的尽头是什么kuyehao.com |